References
- McKenna WJ, Maron BJ, Thiene G. Classification, epidemiology, and global burden of cardiomyopathies. Circ Res. 2017;121(7):722-30; DOI:10.1161/CIRCRESAHA.117.309711.
- Ware SM, Wilkinson JD, Tariq M, Schubert JA, Sridhar A, Colan SD, Shi L, Canter CE, Hsu DT, Webber SA, Dodd DA, Everitt MD, Kantor PF, Addonizio LJ, Jefferies JL, Rossano JW, Pahl E, Rusconi P, Chung WK, Lee T, Towbin JA, Lal AK, Bhatnagar S, Aronow B, Dexheimer PJ, Martin LJ, Miller EM, Sleeper LA, Razoky H, Czachor J, Lipshultz SE, Pediatric Cardiomyopathy Registry Study Group. Genetic causes of cardiomyopathy in children: first results from the pediatric cardiomyopathy genes study. J Am Heart Assoc. 2021;10(9):e017731; DOI:10.1161/JAHA.120.017731.
- Monda E, Rubino M, Lioncino M, Di Fraia F, Pacileo R, Verrillo F, Cirillo A, Caiazza M, Fusco A, Esposito A, Fimiani F, Palmiero G, Pacileo G, CalabroÌ P, Russo MG, Limongelli G. Hypertrophic cardiomyopathy in children: pathophysiology, diagnosis, and treatment of non-sarcomeric causes. Front. Pediatr. 2021;9:632293; DOI:10.3389/fped.2021.632293.
- Salemi VMC, Mohty D, de Altavila SLL, de Melo MDT, Kalil Filho R, Bocchi EA. Insights into the classification of cardiomyopathies: past, present, and future directions. Clinics. 2021;76:e2808; DOI:10.6061/clinics/2021/e2808.
- Marian AJ. Molecular genetic basis of hypertrophic cardiomyopathy. Circ Res. 2021;128(10):1533-53; DOI:10.1161/CIRCRESAHA.121.318346.
- Geske J, Ommen S, Gersh B. Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail. 2018;6(5):364-75; DOI:10.1016/j.jchf.2018.02.010.
- Posafalvi A, Herkert JC, Sinke RJ, van den Berg MP, Mogensen J, Jongbloed JD, van Tintelen JP. Clinical utility gene card for: dilated cardiomyopathy (CMD). Eur J Hum Genet. 2013;21(10); DOI:10.1038/ejhg.2012.276.
- Schaufelberger M. Cardiomyopathy and pregnancy. Heart. 2019;105(20):1543-51; DOI:10.1136/heartjnl-2018-313476.
- Kosobudzki M, Bortkiewicz A. Genetyczne uwarunkowania chorób układu krążenia. Forum Medycyny Rodzinn ej. 2012;6(1):1-13.
- Watkins H, Ashrafian H, Redwood C. Dziedziczne kardiomiopatie. Kardiologia po Dyplomie. 2011;10(9):12-29.
- Burke MA, Cook SA, Seidman JG, Seidman CE. Clinical and mechanistic insights into the genetics of cardiomyopathy. J Am Coll Cardiol. 2016;68(25):2871-86; DOI:10.1016/j.jacc.2016.08.079.
- Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB, American Heart Association, Council on Clinical Cardiology Heart Failure and Transplantation Committee, Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups, Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee, Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups, Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807-16; DOI:10.1161/CIRCULATIONAHA.106.174287.
- Elliott P, Andersson B, Arbustini E, Bilińska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, McKenn a WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A. Klasyfikacja kardiomiopatii. Stanowisko Grupy Roboczej Chorób Mięśnia Sercowego i Osierdzia Europejskiego Towarzystwa Kardiologicznego. Kardiol Pol. 2008;66(5):533-40; DOI: 10.33963/v.kp.80540.
- Yamada T, Nomura S. Recent findings related to cardiomyopathy and genetics. Int J Mol Sci. 2021;22(22):12522; DOI:10.3390/ijms222212522.
- Kimura A. Molecular genetics and pathogenesis of cardiomyopathy. J Hum Genet. 2016;61(1):41-50; DOI:10.1038/jhg.2015.83.
- Brieler J, Breeden MA, Tucker J. Cardiomyopathy: an overview. Am Fam Physician. 2017;96(10):640-6.
- Maj K, Major K, Lelonek M. HFpEF mimics: hypertrophic cardiomyopathy in light of the 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction. Folia Cardiol. 2023;18(4):182-6; DOI:10.5603/fc.96348.
- Marques MA, de Oliveira GA. Cardiac troponin and tropomyosin: structural and cellular perspectives to unveil the hypertrophic cardiomyopathy phenotype. Front Physiol. 2016;7:429; DOI:10.3389/fphys.2016.00429.
- Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-54; DOI:10.1016/j.jacc.2015.01.019.
- Carrier L, Mearini G, Stathopoulou K, Cuello F. Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology. Gene. 2015;573(2):188-97; DOI:10.1016/j.gene.2015.09.008.
- Wolf CM. Hypertrophic cardiomyopathy: genetics and clinical perspectives. Cardiovasc Diagn Ther. 2019;9(Suppl 2):S388-S415; DOI:10.21037/cdt.2019.02.01.
- Akhtar M, Elliott P. The genetics of hypertrophic cardiomyopathy. Glob Cardiol Sci Pract. 2018;2018(3):36; DOI:10.21542/gcsp.2018.36.
- Toepfer CN, Wakimoto H, Garfinkel AC, McDonough B, Liao D, Jiang J, Tai AC, Gorham JM, Lunde IG, Lun M, Lynch TL 4th, McNamara JW, Sadayappan S, Redwood CS, Watkins HC, Seidman JG, Seidman CE. Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin. Sci Transl Med. 2019;11(476):eaat1199; DOI:10.1126/scitranslmed.aat1199.
- Tudurachi BS, Zăvoi A, Leonte A, Țăpoi L, Ureche C, Bîrgoan SG, Chiuariu T, Anghel L, Radu R, Sascău RA, Stătescu C. An update on MYBPC3 gene mutation in hypertrophic cardiomyopathy. Int J Mol Sci. 2023;24(13):10510; DOI:10.3390/ijms241310510.
- Shafaattalab S, Li AY, Gunawan MG, Kim B, Jayousi F, Maaref Y, Song Z, Weiss JN, Solaro RJ, Qu Z, Tibbits GF. Mechanisms of arrhythmogenicity of hypertrophic cardiomyopathy-associated troponin T (TNNT2) variant I79N. Front Cell Dev Biol. 2021;9:787581; DOI:10.3389/fcell.2021.787581.
- Dorsch LM, Kuster DWD, Jongbloed JDH, Boven LG, van Spaendonck- Zwarts KY, Suurmeijer AJH, Vink A, du Marchie Sarvaas GJ, van den Berg MP, van der Velden J, Brundel BJJM, van der Zwaag PA. The effect of tropomyosin variants on cardiomyocyte function and structure that underlie different clinical cardiomyopathy phenotypes. Int J Cardiol. 2021;323:251-8; DOI:10.1016/j.ijcard.2020.08.101.
- Beavers DL, Landstrom AP, Chiang DY, Wehrens XH. Emerging roles of junctophilin-2 in the heart and implications for cardiac diseases. Cardiovascular Res. 2014;103(2):198-205; DOI:10.1093/cvr/cvu151.
- Hof IE, van der Heijden JF, Kranias EG, Sanoudou D, de Boer RA, van Tintelen JP, van der Zwaag PA, Doevendans PA. Prevalence and cardiac phenotype of patients with a phospholamban mutation. Neth Heart J. 2019;27(2):64-9; DOI:10.1007/s12471-018-1211-4.
- Simmerman HK, Jones LR. Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol Rev. 1998;78(4):921-47; DOI:10.1152/physrev.1998.78.4.921.
- Wadmore K, Azad AJ, Gehmlich K. The role of Z-disc proteins in myopathy and cardiomyopathy. Int J Mol Sci. 2021;22(6):3058; DOI:10.3390/ijms22063058.
- Ranta-Aho J, Olive M, Vandroux M, Roticiani G, Dominguez C, Johari M, Torella A, Böhm J, Turon J, Nigro V, Hackman P, Laporte J, Udd B, Savarese M. Mutation update for the ACTN2 gene. Hum Mutat. 2022;43(12):1745-56; DOI:10.1002/humu.24470.
- Mao Z, Nakamura F. Structure and function of filamin C in the muscle Z-disc. Int J Mol. Sci. 2020;21(8):2696; DOI:10.3390/ijms21082696.
- Bang ML, Mudry RE, McElhinn y AS, Trombitás K, Geach AJ, Yamasaki R, Sorimachi H, Granzier H, Gregorio CC, Labeit S Myopalladin, a novel 145-kilodalton sarcomeric protein with multiple roles in Z-disc and I-band protein assemblies. J Cell Biol. 2001;153(2):413-28; DOI:10.1083/jcb.153.2.413.
- Ibrahim M, Siedlecka U, Buyandelger B, Harada M, Rao C, Moshkov A, Bhargava A, Schneider M, Yacoub MH, Gorelik J, Knöll R, Terracciano CM. A critical role for Telethonin in regulating t-tubule structure and function in the mammalian heart. Hum Mol Genet. 2013;22(2):372-83, DOI:10.1093/hmg/dds434.
- Li Z, Ai T, Samani K, Xi Y, Tzeng HP, Xie M, Wu S, Ge S, Taylor MD, Dong JW, Cheng J, Ackerman MJ, Kimura A, Sinagra G, Brunelli L, Faulkner G, Vatta M. A ZASP missense mutation, S196L, leads to cytoskeletal and electrical abnormalities in a mouse model of cardiomyopathy. Circ Arrhythm Electrophysiol. 2010;3(6):646-56; DOI:10.1161/CIRCEP.109.929240.
- Marcus FI, Edson S, Towbin JA. Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians. J Am Coll Cardiol. 2013;61(19):1945-8; DOI:10.1016/j.jacc.2013.01.073
- Jacoby D, McKenna WJ. Genetics of inherited cardiomyopathy. Eur Heart J. 2012;33(3):296-304; DOI:10.1093/eurheartj/ehr260.
- Kim KH, Pereira NL. Genetics of cardiomyopathy: clinical and mechanistic implications for heart failure. Korean Circ J. 2021;51(10):797; DOI:10.4070/kcj.2021.0154.
- Krahn AD, Wilde AAM, Calkins H, La Gerche A, Cadrin-Tourigny J, Roberts JD, Han HC. Arrhythmogenic right ventricular cardiomyopathy. JACC Clin Electrophysiol. 2022;8(4):533-53; DOI:10.1016/j.jacep.2021.12.002.
- Ohno S. The genetic background of arrhythmogenic right ventricular cardiomyopathy. J Arrhythm. 2016;32(5):398-403; DOI:10.1016/j.joa.2016.01.006.
- Campuzano O, Alcalde M, Allegue C, Iglesias A, García-Pavía P, Partemi S, Oliva A, Pascali VL, Berne P, Sarquella-Brugada G, Brugada J, Brugada P, Brugada R. Genetics of arrhythmogenic right ventricular cardiomyopathy. J Med Genet. 2013;50(5):280-9; DOI:10.1136/jmedgenet-2013-101523.
- Bradford WH, Zhang J, Gutierrez-Lara EJ, Liang Y, Do A, Wang TM, Nguyen L, Mataraarachchi N, Wang J, Gu Y, McCulloch A, Peterson KL, Sheikh F. Plakophilin 2 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics. Nat Cardiovasc Res. 2023;2(12):1246-61; DOI:10.1038/s44161-023-00370-3.
- Lee JYW, McGrath JA. Mutations in genes encoding desmosomal proteins: spectrum of cutaneous and extracutaneous abnormalities. Br J Dermatol. 2021;184(4):596-605; DOI:10.1111/bjd.19342.
- Schlipp A, Schinner C, Spindler V, Vielmuth F, Gehmlich K, Syrris P, Mckenna JW, Dendorfer A, Hartlieb E, Waschke J. Desmoglein-2 interaction is crucial for cardiomyocyte cohesion and function. Cardiovasc Res. 2014;104(2):245-57; DOI:10.1093/cvr/cvu206.
- Antoniades L, Tsatsopoulou A, Anastasakis A, Syrris P, Asimaki A, Panagiotakos D, Zambartas C, Stefanadis C, Mckenna WJ, Protonotarios N. Arrhythmogenic right ventricular cardiomyopathy caused by deletions in plakophilin-2 and plakoglobin (Naxos disease) in families from Greece and Cyprus: genotype–phenotype relations, diagnostic features and prognosis. Eur Heart J. 2006;27(18):2208-16; DOI:10.1093/eurheartj/ehl184.
- Smith ED, Lakdawala NK, Papoutsidakis N, Aubert G, Mazzanti A, McCanta AC, Agarwal PP, Arscott P, Dellefave-Castillo LM, Vorovich EE, Nutakki K, Wilsbacher LD, Priori SG, Jacoby DL, McNally EM, Helms AS. Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation. 2020;141(23):1872-84; DOI:10.1161/CIRCULATIONAHA.119.044934.
- Yang Z, Bowles NE, Scherer SE, Taylor MD, Kearney DL, Ge S, Nadvoretskiy VV, DeFreitas G, Carabello B, Brandon LI, Godsel LM, Green KJ, Saffitz JE, Li H, Danieli GA, Calkins H, Marcus F, Towbin JA. Desmosomal dysfunction due to mutations in desmoplakin causes arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Res. 2006;99(6):646-55; DOI:10.1161/01.RES.0000241482.19382.c6.
- Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy. Lancet. 2015;386(9995):813-25; DOI:10.1016/S0140-6736(14)61282-4.
- Lorca R, Martín M, Pascual I, Astudillo A, Molina BD, Cigarrán H, Cuesta-Llavona E, Avanzas P, Reguero JJR, Coto E, Morís C, Gómez J. Characterization of left ventricular non-compaction cardiomyopathy. J. Clin. Med. 2020;9(8):2524; DOI:10.3390/jcm9082524.
- Dong X, Fan P, Tian T, Yang Y, Xiao Y, Yang K, Liu Y, Zhou Y. Recent advancements in the molecular genetics of left ventricular noncompaction cardiomyopathy. Clinica Chimica Acta. 2017;465:40-4; DOI:10.1016/j. cca.2016.12.013.
- Banankhah P, Fishbein GA, Dota A, Ardehali R. Cardiac manifestations of PRKAG2 mutation. BMC Med Genet. 2018;19(1):1-4, DOI:10.1186/s12881-017-0512-6.
- Sternick EB. PRKAG2 cardiomyopathy. Arq Bras Cardiol. 2022;119(5):689-90; DOI:10.36660/ABC.20220694.
- Gong X, Yu P, Wu T, He Y, Zhou K, Hua Y, Lin S, Wang T, Huang H, Li Y. Controversial molecular functions of CBS versus non-CBS domain variants of PRKAG2 in arrhythmia and cardiomyopathy: A case report and literature review. Mol Genet Genomic Med. 2022;10(7):e1962; DOI:10.1002/MGG3.1962.
- Gollob MH. Modulating phenotypic expression of the PRKAG2 cardiac syndrome. Circulation. 2008;117(2):134-5; DOI:10.1161/CIRCULATIONAHA.107.747345.
- Wolf CM, Arad M, Ahmad F, Sanbe A, Bernstein SA, Toka O, Konno T, Morley G, Robbins J, Seidman J, Seidman C, Berul C. Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations. Circulation. 2008;117(2):144-54; DOI:10.1161/CIRCULATIONAHA.107.726752.
- Lopez-Sainz A, Dominguez F, Lopes LR, Ochoa JP, Barriales-Villa R, Climent V, Linschoten M, Tiron C, Chiriatti C, Marques N, Rasmussen TB, Espinosa MA, Beinart R, Quarta G, Cesar S, Field E, Garcia-Pinilla JM, Bilinska Z, Muir AR, Roberts AM, Santas E, Zorio E, Peña-Peña ML, Navarro M, Fernandez A, Palomino-Doza J, Azevedo O, Lorenzini M, García-Álvarez MI, Bento D, Jensen MK, Méndez I, Pezzoli L, Sarquella-Brugada G, Campuzano O, Gonzalez-Lopez E, Mogensen J, Kaski JP, Arad M, Brugada R, Asselbergs FW, Monserrat L, Olivotto I, Elliott PM, Garcia-Pavia P, Barriales R, Larrañaga-Moreira JM, Alonso-García D, Cárdenas-Reyes IJ, Cicerchia M, García-Ferro G, García-Hernández S, Nöel-Bröger M, Ortiz M, Azevedo P, Bispo J, Mota T, Fernandes R, Costa H, Doza JP, Salguero-Bodes R, Valverde-Gomez M, Espinosa MA, Mendez I, Cobo-Marcos M, Domínguez F, Escobar L, González-López E, López-Sainz Á, Segovia-Cubero J, Vilches S, Garcia-Pinilla JM, Robles-Mezcua A, López-Garrido M, Hidalgo LM, Abad VD, Sabater-Molina M, Gimeno-Blanes JR, Barton PJ, Cook SA, Ware JS, Syrris P, Truszkowska G, Michalak E, Ploski R, Bilinska Z, Asselbergs F, Baas AF, Dooijes D. Clinical features and natural history of PRKAG2 variant cardiac glycogenosis. J Am Coll Cardiol. 2020;76(2):186-97; DOI:10.1016/J.JACC.2020.05.029.
- Cheng Z, Fang Q. Danon disease: focusing on heart. J Hum Genet. 2012;57(7):407-10; DOI:10.1038/jhg.2012.72.
- Endo Y, Furuta A, Nishino I. Danon disease: a phenotypic expression of LAMP-2 deficiency. Acta Neuropathol. 2015;129(3):39188; DOI:10.1007/s00401-015-1385-4.
- Cenacchi G, Papa V, Pegoraro V, Marozzo R, Fanin M, Angelini C. Review: Danon disease: review of natural history and recent advances. Neuropathol Appl Neurobiol. 2020;46(4):303-22; DOI:10.1111/nan.12587.
- Arad M. Cardiac Danon disease: insights and challenges. Int J Cardiol. 2017;245:211-2; DOI:10.1016/j.ijcard.2017.07.106.
- Rowland TJ, Sweet ME, Mestroni L, Taylor MRG. Danon disease – dysregulation of autophagy in a multisystem disorder with cardiomyopathy. J Cell Sci. 2016;129(11):2135-43; DOI:10.1242/jcs.184770.
- Brambatti M, Caspi O, Maolo A, Koshi E, Greenberg B, Taylor MRG, Adler E. Danon disease: gender differences in presentation and outcomes. Int J Cardiol. 2019;286:92-8; DOI:10.1016/J.IJCARD.2019.01.020.
- El-Hattab AW, Scaglia F. Mitochondrial cardiomyopathies. Front Cardiovasc Med. 3:(25); DOI:10.3389/fcvm.2016.00025.
- Meyers DE, Haseeb F, Basha I, Koenig MK. Mitochondrial cardiomyopathy. Tex Heart Inst J. 2013;40(4):385-94.
- Abriel H, Zaklyazminskaya E V. Cardiac channelopathies: genetic and molecular mechanisms. Gene. 2013;517(1):1-11; DOI:10.1016/J. GENE.2012.12.061.
- Fernández-Falgueras A, Sarquella-Brugada G, Brugada J, Brugada R, Campuzano O. Cardiac channelopathies and sudden death: recent clinical and genetic advances. Biology. 2017;6(1):7; DOI:10.3390/BIOLOGY6010007.
- Skinner JR, Winbo A, Abrams D, Vohra J, Wilde AA. Channelopathies that lead to sudden cardiac death: clinical and genetic aspects. Heart Lung Circ. 2019;28(1):22-30; DOI:10.1016/J.HLC.2018.09.007.
- Dotzler SM, Kim CSJ, Gendron WAC, Zhou W, Dan Ye, Bos JM, Tester DJ, Barry MA, Ackerman MJ. Suppression-replacement KCNQ1 gene therapy for type 1 long QT syndrome. Circulation. 2021;143(14):1411-25; DOI:10.1161/CIRCULATIONAHA.120.051836.
- Jespersen T, Grunnet M, Olesen SP. The KCNQ1 potassium channel: from gene to physiological function. Physiology. 2005;20(6):408-16; DOI:10.1152/physiol.00031.2005.
- Kekenes-Huskey PM, Burgess DE, Sun B, Bartos DC, Rozmus ER, Anderson CL, January CT, Eckhardt LL, Delisle BP. Mutation-specific differences in Kv7.1 (KCNQ1) and Kv11.1 (KCNH2) channel dysfunction and long QT syndrome phenotypes. Intern J of Molec Scien 2022;23(13):7389; DOI:10.3390/ijms23137389.
- Fowler ED, Zissimopoulos S. Molecular, subcellular, and arrhythmogenic mechanisms in genetic RyR2 disease. Biomolecules. 2022;12(8):1030; DOI:10.3390/biom12081030.
- McNair WP, Ku L, Taylor MR, Fain PR, Dao D, Wolfel E, Mestroni L, Familial Cardiomyopathy Registry Research Group. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation. 2004;110(15):2163-7; DOI:10.1161/01. CIR.0000144458.58660.BB.
- Wilde AAM, Amin AS. Clinical spectrum of SCN5A mutations: long QT syndrome, Brugada syndrome, and cardiomyopathy. J Am Coll Cardiol EP. 2018;4(5):569-79; DOI:10.1016/j.jacep.2018.03.006.
- Bienengraeber M, Olson TM, Selivanov VA, Kathmann EC, O’Cochlain F, Gao F, Karger AB, Ballew JD, Hodgson DM, Zingman LV, Pang YP, Alekseev AE, Terzic A. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat Genet. 2004;36(4):382-7; DOI:10.1038/ng1329.